- State of the market: Are generic drugs approaching their peak?
- Facing pharmacy trends for the remainder of the year
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Senate passes Drug Quality and Security Act
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
BALTIMORE — The Food and Drug Administration has approved an additional strength of a generic drug made by Lupin Pharmaceuticals for high blood pressure, Lupin said Wednesday.
Lupin announced the approval of amlodipine besylate and benazepril hydrochloride capsules in the 5-mg/40-mg and 10-mg/40-mg strengths. The company already markets the drug in the 2.5-mg/10-mg, 5-mg/10-mg, 5-mg/20-mg and 10-mg/20-mg strengths.
The drug is a generic version of Novartis’ Lotrel, which had sales of $290 million during the 12-month period ended in March, according to IMS Health.